New research presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025 reveals that people with ...

During his tenure at Roche's Genentech, ophthalmologist Jason Ehrlich, M.D., Ph.D., supported the development of the ...

Recently initiated Phase 1b/2 multiple ascending dose study intended to assess safety and efficacy in nAMD patients receiving four initial ...

The use of anticoagulants or antiplatelets was linked to a higher risk of intraocular hemorrhage requiring vitrectomy in ...

An analysis of pivotal phase 3 trials shows supplements to arrest age-related macular degeneration have no effect on ...

South Korean biotech Alteogen (KOSDAQ:196170) has secured European Commission clearance for Eyluxvi (ALT-L9), its biosimilar ...

LumiThera's key innovation is a device for use by ophthalmologists that improves vision and slows its loss, with a focus on ...

Kalaris Therapeutics initiates a phase 1b/2 study for TH103, targeting neovascular age-related macular degeneration and ...

OLN324 targets both VEGF and Ang2, the same mechanism of action as Roche’s Vabysmo, the Swiss giant’s multi-blockbuster ...

While pivotal research on therapies for neovascular age-related macular degeneration (nAMD) and geographic atrophy (GA) ...